AbbVie to present 22 inflammatory bowel disease abstracts at ACG 2026 meeting

AbbVie said it will present 22 scientific abstracts from its inflammatory bowel disease portfolio at the American College of Gastroenterology 2026 Annual Scientific Meeting in Nashville, Tennessee, from October 9 to 14, 2026.

AbbVie said that in the Phase 3 AFFIRM study, subcutaneous SKYRIZI (risankizumab-rzaa) achieved higher rates of clinical remission and endoscopic response than placebo at Week 12 in patients with moderately to severely active Crohn's disease. The company said rates for all endpoints remained numerically higher through Week 24 among clinical responders.

AbbVie also presented open-label extension analyses. In the FORTIFY study, clinical and endoscopic remission rates were generally maintained or improved through 144 weeks across disease locations, and 74.5% of patients with fistulizing Crohn's disease had no draining fistulas after five years of treatment with risankizumab.

AbbVie said real-world data from the Veterans Affairs health system showed that 93.3% of patients with fistulizing disease and 76.9% of patients with stricturing disease who remained on RINVOQ (upadacitinib) achieved clinical remission and corticosteroid-free remission. Ryan DeMasi, M.D., of AbbVie, said people living with IBD want treatments that meaningfully reduce the burden of their disease.